Dose radiotherapy for lung cancer treatment.

Overview

No summary available.

Registry

who.int

Start Date

August 9, 2010

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•a) Men or women who are between 18 and 65 years of age
•b)Subjects with histologically or cytologically confirmed non\-small cell carcinoma
•c)Stage III
•d)Karnofsky index \= 70 %.
•e)Forced Expiratory Volume in 1 second (FEV1\) equal or greater than 1 Liter.
•f)Measurable disease on CT scan of radiotherapy planning.
•g)Lung percentage (both lungs excluding PTV or planned volume) that will recive a dose \> 20 Gy (V20 ) must be less or equal of 30 %.
•h)The esophagus volume vill be delimited withoth excluding PTV. The percentage of esophagus that will recive a dose \> 60 Gy (V60\) mus be less or equal to 30% and the mean dose in esophagus (MED) less or equal to 34 Gy.
•i) Concomitanr chemotherapy.
•j) Biochemistry and blood analysis. Neutrophils \= 1500/µl; platelets \= 100000/µl; creatinine \= 2 mg/dl, hepatic transaminases \< 2,5 times the upper limit of normality, bilirubin \< 1,5 times upper limit of normality; alkaline phosphatase \< 2,5 times the upper limit of normality.

•a)Small\-cell carcinoma
•b)Pleural or pericardic effusion with positive cytology
•c)Supraclavicular adenopathy positive
•d)Superior vena cava syndrome
•e)Previous thoracic radiation.
•f)Sensitive neuropathy \> grade I following NCI CTCv 3\.0 criteria
•g)Severe comorbididy (acute myocardial infacrtion within 3 nmonth of inclusion, cardiac arrithmia or non\-controlled hypertension )
•h)Treatments that can interfere with the pharmacokinetic or pharmacodynamic of (18F)\-FMISO.
•i)Pregnant or breast\-feeding females
•j)Subjects older than 65 years.